cisplatin + ifosfamide + mitomycin c

The combination of cisplatin, ifosfamide, and mitomycin C—commonly referred to as the MIC regimen—is a multi-agent chemotherapy protocol primarily used in the treatment of advanced non-small-cell lung cancer (NSCLC). Each component is a cytotoxic small molecule with distinct mechanisms: - Cisplatin is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function. - Ifosfamide is an alkylating agent that induces DNA strand breaks through alkylation. - Mitomycin C acts as an antitumor antibiotic that also crosslinks DNA after enzymatic activation. This combination has demonstrated improved response rates and survival in NSCLC compared to single-agent or less intensive regimens. However, it is associated with significant toxicities including nephrotoxicity, myelosuppression (leukopenia, thrombocytopenia), and anemia. Modified dosing schedules have been explored to reduce toxicity while maintaining efficacy[1][2][3].

Other names

MIC regimen